Ultragenyx Raises $75 Million Series B, Prepares For A 2014 IPO
This article was originally published in The Pink Sheet Daily
Ultragenyx raised $75 million in a Series B financing led by Adage Capital Partners. The funding will support the biotech’s two lead programs that are meant to treat ultra-rare genetic disorders and will position the company for an initial public offering.
You may also be interested in...
Ultragenyx Plans Five Clinical Trials For 2014
The rare disease biotech is confident it can move all of its programs forward and has no interest in selling its commercialization rights to a Big Pharma partner.
Deals Of The Week: Hunting For Dengue Fever Drugs Amid Climate Change
Plus news of deals between Sanofi and Pozen, Otsuka and Astex, Santhera and Takeda, Ultragenyx and Kyowa, Baxter and Coherus Biosciences, Novartis and Regenerex, and more.
Biopharma Dealmaking Quarterly Statistics, Q4 2012
At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.